基于mRNA的组合疗法用于由单酸诱导的由炎症驱动的骨关节炎
Yuki Terai1,2,3, Erica Yada2,3,4, Hideyuki Nakanishi1,2
1Clinical Biotechnology Team, Center for Infectious Disease Education and Research (CiDER), The University of Osaka, Suita 565-0871, Japan.
Pharmaceutics
|October 29, 2025
概括
使用多复合纳米细胞的双信使RNA (mRNA) 疗法通过减少炎症和保护软骨来有效治疗骨关节炎. 结合IL-1受体对抗剂 (IL-1Ra) 和RUNX1mRNA,为关节健康提供了协同效益.
科学领域:
- 生物医学工程 生物医学工程
- 分子医学是分子医学.
- 类风湿病学 类风湿病学
背景情况:
- 骨关节炎 (OA) 是一种退行性关节疾病,具有有限的疾病修饰治疗方法.
- 使者RNA (mRNA) 疗法显示了OA的潜力,但需要有效的传递系统.
- 目前的OA疗法往往无法解决复杂的炎症和退行性过程.
研究的目的:
- 在大鼠OA模型中使用多重复纳米细胞来评估关节内mRNA治疗.
- 评估IL-1受体对抗剂 (IL-1Ra) mRNA和RUNX1 mRNA的单独和联合作用.
- 研究双重mRNA治疗骨关节炎的潜力.
主要方法:
- 在老鼠中使用单酸 (MIA) 诱导由炎症驱动的OA.
- 通过非炎症多重复合纳米细胞传递治疗性mRNA的关节内输送.
- 评估结膜炎症,软骨完整性,软骨细胞活力和亚软骨骨变化.
主要成果:
- IL-1Ra mRNA显著降低了结膜炎症,疼痛和胀.
- RUNX1mRNA支持了状细胞的活力和软骨结构.
- 结合IL-1Ra和RUNX1mRNA疗法证明了协同性冠状腺保护和保存的亚冠状腺骨.
结论:
- 有效控制关节炎症对于RUNX1mRNA在OA治疗疗效至关重要.
- 针对炎症和软骨平衡的双重mRNA疗法为OA提供了一个有前途的策略.
- 多复合纳米细胞为OAmRNA治疗提供了可行的非侵入性输送系统.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
01:29Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
01:29Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449